Search Result

Results for "

ER degrader

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (7) AUTACs (1) Autophagy (2) AUTOTACs (1) Bcl-2 Family (1) Caspase (1) Cytochrome P450 (3) Deubiquitinase (3) E1/E2/E3 Enzyme (1) E3 Ligase Ligand-Linker Conjugates (4) Epigenetic Reader Domain (1) Estrogen Receptor/ERR (79) Indoleamine 2,3-Dioxygenase (IDO) (1) Isotope-Labeled Compounds (4) Ligands for E3 Ligase (1) Ligands for Target Protein for PROTAC (7) METTL3 (1) Microtubule/Tubulin (1) Molecular Glues (1) Potassium Channel (1) PROTAC Linkers (1) PROTAC-Linker Conjugates for PAC (1) PROTACs (25) SNIPERs (3)
By Research Areas:	Cancer (91) Infection (1) Inflammation/Immunology (2)
Click Chemistry:	Azide (2)

Inhibitors & Agonists

Screening Libraries

Isotope-Labeled Compounds

Click Chemistry

Targets Recommended: ER-phagy

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-163812

*ER degrader* 9**	Molecular Glues Estrogen Receptor/ERR	Cancer
ER degrader 9 (compound 1), a bifunctional molecular glue, is a potent estrogen receptor (ER) degrader with a DC₅₀ of ≤10 nM in MCF-7 cells. ER degrader 9 can be used for the research of breast cancer .

HY-149970

*ER degrader* 5**	Estrogen Receptor/ERR	Cancer
ER degrader 5 is a potent estrogen receptor (ER) degrader. ER degrader 5 shows anti-proliferation activity. ER degrader 5 can be used for the research of breast cancer .

HY-155196

*ER degrader* 6**	Estrogen Receptor/ERR	Cancer
ER degrader 6 (compound 35s) is a potent Estrogen Receptor (ER)α degrader. ER degrader 6 disrupts the microtubule network by restraining tubulin polymerization. ER degrader 6 suppresses tumor growth without noticeable poisonousness .

HY-170377

*ER degrader* 10**	Estrogen Receptor/ERR Potassium Channel	Cancer
ER degrader 10 (Compound 51) is a selective, orally active degrader and antagonist for estrogen receptor (ER) with a DC₅₀ of 0.43 nM and an IC₅₀ of 0.56 nM. ER degrader 10 inhibits the proliferation of ER-positive cells with IC₅₀s of 0-15 nM. ER degrader 10 exhibits a weak inhibitory activity against hERG channel with an IC₅₀ >40 μM. ER degrader 10 is blood-brain barrier penetrable with a brain/plasma ratio (Kp) of 3.05. ER degrader 10 exhibits antitumor efficacy in mice model .

HY-149969

*ER degrader* 4**	Estrogen Receptor/ERR	Cancer
ER degrader 4 is a selective and orally active estrogen receptor degrader. ER degrader 4 has anti-tumor activity .

HY-155197

*ER degrader* 7**	Microtubule/Tubulin Estrogen Receptor/ERR	Cancer
ER degrader 7 (Compound 35t) is an ERα and ERβ degrader. ER degrader 7 inhibits tubulin polymerization. ER degrader 7 inhibits cell viability with IC₅₀s of 0.06, 2.56, 15.84, 1.59, 1.67, 1.37 μM for MCF-7, T47D, MCF-10A, LCC2, T47D D538G, and T47D Y537S cells respectively. ER degrader 7 also inhibits breast cancer tumor growth .

HY-142926

*ER degrader* 2**	Estrogen Receptor/ERR	Cancer
ER degrader 2 is a potent degrader of estrogen receptor (ER). The estrogen signaling system plays an important role in regulating cell growth, differentiation and apoptosis. ER degrader 2 has the potential for the research of cancer diseases (extracted from patent CN112830919A, compound 1) .

HY-142925

*ER degrader* 1**	Estrogen Receptor/ERR	Cancer
ER degrader 1 is a potent degrader of estrogen receptor (ER). The estrogen signaling system plays an important role in regulating cell growth, differentiation and apoptosis. ER degrader 1 has the potential for the research of cancer diseases (extracted from patent WO2021139756A1, compound 11) .

HY-142927

*ER degrader* 3**	Estrogen Receptor/ERR	Cancer
ER degrader 3 is a potent degrader of estrogen receptor (ER). The estrogen signaling system plays an important role in regulating cell growth, differentiation and apoptosis. ER degrader 3 has the potential for the research of cancer diseases (extracted from patent WO2018233591A1, compound 1) .

HY-145073

*PROTAC ER Degrader-10*	PROTACs Estrogen Receptor/ERR	Cancer
PROTAC ER Degrader-10 is a potent PROTAC ER degrader and can be used for cancer research. PROTAC ER Degrader-10 is extracted from patent WO2021133886, example 36.

HY-135309

*PROTAC ER Degrader-4*	PROTACs Estrogen Receptor/ERR	Cancer
PROTAC ER Degrader-4 is a von Hippel-Lindau-based PROATC estrogen receptor (ER) degrader, binding to ER with an IC50 of 0.8 nM. PROTAC ER Degrader-4 induces ER degradation in MCF-7 cells with an IC₅₀ of 0.3 nM .

HY-168270

*PROTAC ER Degrader-11*	PROTACs Estrogen Receptor/ERR	Cancer
PROTAC ER Degrader-11 (Example 26-1) is a potent PROTAC ER degrader, with the IC₅₀ of 0.66 nM. PROTAC ER Degrader-11 plays an important role in cancer research(Sturcture Note:(Blue: Cereblon ligand (HY-W797329), Black: linker (HY-W262798)；Pink: ER ligand (HY-168271)) .

HY-160264

*PROTAC ER Degrader-12*	PROTACs Estrogen Receptor/ERR	Cancer
PROTAC ER Degrader-12 (Compound 70) is an estrogen receptor PROTAC degrader (DC₅₀: <10 nM), and inhibits MCF-7 proliferation (DC₅₀: <10 nM). PROTAC ER Degrader-12 has anticancer effect. Pink: ER ligand (HY-169978); Blue: E3 ligase ligand (HY-138793); Black: linker (HY-30756) .

HY-128527

*PROTAC ER Degrader-3*	PROTACs Estrogen Receptor/ERR	Cancer
PROTAC ER Degrader-3 is an intermediate for synthesis of PAC. PAC, consists the ADCs linker and PROTACs, conjugated to an antibody. PAC extracts from patent WO2017201449A1, compound LP2. PAC conjugated to an antibody is a more marked estrogen receptor-alpha (ERα) degrader compared to PROTAC (without Ab) .

HY-128528

*PROTAC ER Degrader-2*	PROTACs Estrogen Receptor/ERR	Cancer
PROTAC ER Degrader-2 is an intermediate for synthesis of PAC. PAC, consists the ADCs linker and PROTACs, conjugated to an antibody. PAC extracts from patent WO2017201449A1, compound LP2. PAC conjugated to an antibody is a more marked estrogen receptor-alpha (ERα) degrader compared to PROTAC (without Ab) .

HY-170332

*PROTAC ER Degrader-15*	PROTACs Estrogen Receptor/ERR	Cancer
PROTAC ER Degrader-15 (Compound 40) is an orally active degrader of the estrogen receptor (ER) with anticancer activity，which can be used in breast cancer research (Pink: Target Protein Ligand (HY-170334); Black: Linker (HY-30756); Blue: E3 Ligase Ligand (HY-138793); E3 Ligase Ligand-Linker Conjugate (HY-169979)) .

HY-170340

*PROTAC ER Degrader-14*	PROTACs Estrogen Receptor/ERR	Cancer
PROTAC ER Degrader-14 (compound 86) is a PTORAC-type Estrogen Receptor/ERR degrader, which is composed of E3 ubiquitin ligase ligand (blue part) (S)-Deoxy-thalidomide (HY-168055), PROTAC Linker (black part) N-Boc-piperazine (HY-30105) and target protein ligand (red part) ER ligand-6 (HY-170341). Among them, E3 ligase + Linker constitute tert-Butyl (S)-4-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)piperazine-1-carboxylate (HY-W998234) .

HY-168101

*ERα degrader* 11**	Estrogen Receptor/ERR	Cancer
ERα degrader 11 (compound B16) is a selective ERα degrader that can be used as an estrogen receptor probe to investigate ER status in ER-positive breast cancer cells .

HY-133017

Amcenestrant 3 Publications Verification SAR439859	Estrogen Receptor/ERR	Cancer
SAR439859 (compound 43d) is an orally active, non-steroidal, and selective estrogen receptor degrader (SERD). SAR439859 is an effective ER antagonist with ER degradation activity, an EC₅₀ of 0.2 nM. SAR439859 can show potent anti-tumor effects and limited cross-resistance in ER ⁺ breast cancer.

HY-141551

GNE-274	Estrogen Receptor/ERR	Cancer
GNE-274 is a structural analog of the ER degrader GDC-0927 and is a non-degrader. GNE-274 does not induce conversion of ER in breast cancer cell lines and functions as a partial ER agonist (partial ER agonist). GNE-274 increases the chromatin accessibility of ER-DNA binding sites, whereas GDC-0927 does not. GNE-274 is an effective ER ligand binding domain (LBD) inhibitor. GNE-274 can be used in cancer research.

HY-168099

*ERα degrader* 10**	Estrogen Receptor/ERR	Cancer
ERα degrader 10 is a selective and orally active estrogen receptor α (ERα) degrader. ERα degrader 10 exhibits potent ERα binding affinity (IC₅₀ of 24.0 nM) and degradation ability (EC₅₀ of 5.3 nM). ERα degrader 10 degrades ERα through the proteasome-mediated pathway. ERα degrader 10 can be used for the study of breast cancer .

HY-149295

*PROTAC ERα Degrader-4*	PROTACs Estrogen Receptor/ERR Apoptosis	Cancer
PROTAC ERα Degrader-4 (Compound ZD12) is a highly potent and selectivePROTAC ERα degrader (K_i: 5.08 μM). PROTAC ERα Degrader-4 contains OBHSAs, linker and E3 ligase ligands. PROTAC ERα Degrader-4 shows excellent cell inhibitory and ERα degradation activity against Tamoxifen-sensitive and -resistant ER ⁺ breast cancer (BC) cells and ERα-mutated BC cells. PROTAC ERα Degrader-4 can induce apoptosis and can be used for cancer research.

HY-157765

*PROTAC ERα Degrader-6*	PROTACs Estrogen Receptor/ERR	Cancer
PROTAC ERα Degrader-6 (compound A2) is a potent PROTAC degrader of ERα, with IC₅₀ of 0.11 μM in MCE-7 cells. PROTAC ERα Degrader-6 has anti-tumor effect. PROTAC ERα Degrader-6 is a fluorescent probes with Em of 582 nm that enable real-time visualization of ERα protein degradation .

HY-163680

*ERα degrader* 9**	Estrogen Receptor/ERR Cytochrome P450	Cancer
ERα degrader 9 is a dual targeting ligand for estrogen receptor α (ERα) and aromatase (ARO). ERα degrader 9 can be utilized for synthesis of PROTAC ERα Degrader-9 (HY-163679) .

HY-149081

*ERα degrader* 6**	Estrogen Receptor/ERR Cytochrome P450	Cancer
ERα degrader 6 (Compound 31q) is an ERα degrader (K_I: 75 nM). ERα degrader 6 also inhibits ARO with an IC₅₀ of 37.7 nM. ERα degrader 6 inhibits tumor growth in MCF-7 tumor xenograft model. ERα degrader 6 can be used for breast cancer research .

HY-112098

*PROTAC ERα Degrader-1* 1 Publications Verification	PROTACs Estrogen Receptor/ERR	Cancer
PROTAC ERα Degrader-1 comprises an ubiquitin E3 ligase binding group, a linker and a protein binding group. PROTAC ERα Degrader-1 extracts from patent WO2017201449A1, compound P1. PROTAC ERα Degrader-1 is an estrogen receptor-alpha (ERα) degrader.

HY-146267

*ERα degrader* 5**	Estrogen Receptor/ERR	Cancer
ERα degrader 5 (Compound 40) is a selective, orally bioavailable estrogen receptor (ER) degrader (SERD) with an EC₅₀ of 1.1 nM against ERα. ERα degrader 5 shows antitumor effect in vivo .

HY-111846

*PROTAC ERα Degrader-2* 1 Publications Verification	SNIPERs PROTACs Estrogen Receptor/ERR	Cancer
PROTAC ERα Degrader-2 comprises a IAP ligand binding group, a linker and an estrogen receptor α (ERα) binding group. PROTAC ERα Degrader-2 is an ERα degrader. Maximal ERα degradation at 30 μM concentration in human mammary tumor MCF7 cells. Degradation inducers based on cIAP1 are called specific and non-genetic IAP-dependent protein erasers (SNIPERs) .

HY-145071

*PROTAC ERα Y537S degrader-1*	PROTACs Estrogen Receptor/ERR	Cancer
PROTAC ERα Y537S degrader-1 comprises a ubiquitin E3 ligase binding group, a linker and a protein binding group. PROTAC ERα Y537S degrader-1 extracts from patent WO2021143822, example 12. PROTAC ERα Y537S degrader-1 is an estrogen receptor-alpha (ERα) Y537S degrader .

HY-168271

ER ligand-2	Ligands for Target Protein for PROTAC Estrogen Receptor/ERR	Cancer
ER ligand-2 (Ligands for Target Protein for Compound 24) is the ligand of ER. ER ligand-2 can be used for synthesis PROTAC ER Degrader-11 (HY-168270) .

HY-170806

*ERα degrader* 12**	Estrogen Receptor/ERR	Cancer
ERα degrader 12 (Compound RA3) is an estrogen receptor α (ERα) degrader with antitumor properties. ERα degrader 12 induces pronounced tumor growth inhibition in a breast cancer xenograft mouse model .

HY-170341

ER ligand-6	Ligands for Target Protein for PROTAC Estrogen Receptor/ERR	Cancer
ER ligand-6 is a target protein ligand of PROTAC ER Degrader-14 (HY-170340) .

HY-112100

*PROTAC ERα Degrader-5*	PROTAC-Linker Conjugates for PAC Estrogen Receptor/ERR	Cancer
PROTAC ERα Degrader-5 (compound LP2) consists an ADC linker and a PROTAC, whcih can be conjugated to an antibody to form PACs. PROTAC ERα Degrader-5 conjugated to an antibody is a more marked estrogen receptor-alpha (ERα) degrader compared to PROTAC (without Ab) .

HY-160562

*PROTAC ERα Degrader-7*	PROTACs Estrogen Receptor/ERR	Cancer
PROTAC ERα Degrader-7 (compound i-320) is a potent estrogen receptor alpha(ERα) PROTAC degrader with a DC₅₀ value of 0.000006 µM. PROTAC ERα Degrader-7 comprises a cereblon-binding moiety LBM linked to a ligand ERBM that binds ERα and comprises a benzofused partially saturated 6-membered carbocyclic or heterocyclic ring .

HY-161692

*ERα degrader* 8**	Estrogen Receptor/ERR	Cancer
ERα degrader 8 (Compound 18j) is a selective Estrogen Receptor degrader. ERα degrader 8 is degrader to MCF-7 cells with IC₅₀ value of 0.15 μM .

HY-132194

*ERα degrader-2*	Estrogen Receptor/ERR	Cancer
ERα degrader-2 is a selective estrogen receptor degrader (SERD) with potent binding affinity with ERα (IC₅₀=17.1 nM), good degradation efficacy (EC₅₀=0.3 nM). ERα degrader-2 exhibits favorable pharmacokinetic properties and excellent agentgability, can be used for HER ⁺ breast cancer research .

HY-155492

*ERα degrader* 7**	Estrogen Receptor/ERR	Cancer
ERα degrader 7 (compound B1) is a potent ERα degrader with an IC₅₀ of 14.6 nM and a DC₅₀ of 9.7 nM, respectively. ERα degrader 7 shows excellent antitumor activity, indicating its potential to evolve as a promising selective estrogen-receptor degrader (SERD) for breast cancer research .

HY-160563

*PROTAC ERα Degrader-8*	PROTACs Estrogen Receptor/ERR	Cancer
PROTAC ERα Degrader-8 (compound ii-56) is a potent PROTAC degrader of Erα, with DC₅₀ of 0.000006 μM in MCF7 cells .

HY-169978

ER ligand-3	Ligands for Target Protein for PROTAC	Cancer
ER ligand-3 is a PROTAC target protein ligand (Ligands for Target Protein for PROTACs). ER ligand-3 can be used for the synthesis of PROTAC ER Degrader-12 (HY-160264) .

HY-144306

*ERα degrader* 4**	Estrogen Receptor/ERR Apoptosis	Cancer
ERα degrader 4 is an excellent and selective estrogen receptor α (ERα) degrader (IC₅₀ of 0.31, 0.41 and 0.48 μM in MDA-MB-231, MCF-7 and MCF-7/ADR cells, respectively). ERα degrader 4 has potent inhibitory activity against MCF-7 cell lines. ERα degrader 4 is a potential SERDs candidate for the research of breast cancer .

HY-170334

ER ligand-7	Estrogen Receptor/ERR Ligands for Target Protein for PROTAC	Cancer
ER ligand-7 is the ligand for estrogen receptor, and can be used for synthesis of PROTAC ER Degrader-15 (HY-170332) as ligand for target protein .

HY-163679

*PROTAC ERα Degrader-9*	Estrogen Receptor/ERR Cytochrome P450 PROTACs Apoptosis	Cancer
PROTAC ERα Degrader-9 (Compound 18c) is a dual-targeting PROTAC degrader, which degrades estrogen receptor α (ERα) and aromatase (ARO). PROTAC ERα Degrader-9 binds to ERα with a K_i of 0.25 μM, inhibits ARO with an IC₅₀ of 4.6 μM. PROTAC ERα Degrader-9 inhibits the proliferation of MCF-7 wildtype (IC₅₀=0.54 μM) and ERα mutants MCF-7 ^EGFR (IC₅₀=0.075 μM), MCF-7 ^D538G (IC₅₀=0.31 μM), MCF-7 ^Y537S (IC₅₀=2.3 μM), downregulates the expressions of ERS1 and MYC. PROTAC ERα Degrader-9 arrests the cell cycle at G2/M, induces apoptosis in MCF-7. PROTAC ERα Degrader-9 exhibits antitumor efficacy in mouse models. (Pink: ligand for target protein (HY-163680); Black: linker (HY-W007559); Blue: ligand for E3 ligase (HY-112078))

HY-170339

ER ligand-5	Estrogen Receptor/ERR Ligands for Target Protein for PROTAC	Cancer
ER ligand-5 is the ligand for estrogen receptor, that can be used as ligand for target protein for PROTAC synthesis of PROTAC ERα Degrader-10 (HY-170336) .

HY-129619

SNIPER(ER)-87	SNIPERs Estrogen Receptor/ERR	Cancer
SNIPER(ER)-87 consists of an inhibitor of apoptosis protein (IAP) ligand LCL161 derivative that is conjugated to the estrogen receptor α (ERα) ligand 4-hydroxytamoxifen by a PEG linker, and efficiently degrades the ERα protein (IC₅₀=0.097 μM). SNIPER(ER)-87 preferentially recruits XIAP to ERα in the cells, and XIAP is the primary E3 ubiquitin ligase responsible for the SNIPER(ER)-87-induced ERα degradation .

HY-170336

*PROTAC ERα Degrader-10*	PROTACs Estrogen Receptor/ERR	Cancer
PROTAC ERα Degrader-10 (Compound 160a) is an orally active degrader for ERα with DC₅₀ of 0.37-1.1 nM, in cells MCF7, T47D and CAMA-1. PROTAC ERα Degrader-10 exhibits antitumor efficacy in mouse model . (Pink: ligand for target protein (HY-170339); Black: linker (HY-30105); Blue: ligand for E3 ligase Cereblon (HY-168055))

HY-137144

Fulvestrant-3-boronic acid ZB716	Estrogen Receptor/ERR	Cancer
Fulvestrant-3-boronic acid is an orally active ERα inhibitor, which binds to ERα competitively (IC₅₀ = 4.1 nM) and effectively degrades ERα in breast cancer cells .

HY-46340

AZD9496 deacrylic acid phenol	Ligands for Target Protein for PROTAC	Cancer
AZD9496 deacrylic acid phenol is a fragment of target protein ligand of PROTAC ER Degrader-4 (HY-135309) .

HY-19822

Elacestrant 10+ Cited Publications RAD1901	Estrogen Receptor/ERR	Cancer
Elacestrant (RAD1901) is an orally available and selective estrogen receptor degrader (SERD) with IC₅₀s of 48 and 870 nM for ERα and ERβ, respectively. Elacestrant also can inhibit growth of ER ⁺ breast cancer cell lines in vitro and in vivo .

HY-122825

SNIPER(ER)-110	SNIPERs Estrogen Receptor/ERR	Cancer
SNIPER(ER)-110 consists of a IAP ligand and an estrogen ligand, connected by a linker. SNIPER(ER)-51 induces estrogen receptor (ER) protein degradation with DC₅₀s of <3 nM and 7.7 nM after 4 h and 48 h, respectively .

HY-19822A

Elacestrant dihydrochloride 10+ Cited Publications RAD1901 dihydrochloride	Estrogen Receptor/ERR	Cancer
Elacestrant (RAD1901) dihydrochloride is an orally available and selective estrogen receptor degrader (SERD) with IC₅₀s of 48 and 870 nM for ERα and ERβ, respectively. Elacestrant dihydrochloride also can inhibit growth of ER ⁺ breast cancer cell lines in vitro and in vivo .

Cat. No.	Product Name

HY-L129

Target Protein Ligand Library

56 compounds

Proteolysis-targeting chimera (PROTAC) has been developed to be a useful technology for targeted protein degradation. PROTACs consist of a ligand for E3 ligase (E3 ligase binder), a linker and a ligand (mostly small-molecule inhibitor) for protein of interest（target binder）. Upon binding to the target protein, the PROTACs can recruit E3 for target protein ubiquitination, which is subjected to proteasome-mediated degradation. Therefore, PROTACs execute their functions by degrading the target proteins rather than inhibiting them, which has a great superiority in overcoming resistance caused by target mutation or overexpression. To date, PROTAC technology has been applied to a variety of targets, including AR, ER, BTK, BET, and BCR-ABL to overcome resistance.

MCE carefully prepared a unique collection of 56 ligands for target proteins, which have been reported to be used in PROTAC design. MCE Target Protein Ligand Library is a useful tool for PROTAC development.

Cat. No.	Product Name	Chemical Structure

HY-19822S2

Elacestrant-d10
Elacestrant-d₁₀ is the deuterium labeled of Elacestrant (HY-19822). Elacestrant is an orally available and selective estrogen receptor degrader (SERD) with IC₅₀s of 48 and 870 nM for ERα and ERβ, respectively. Elacestrant also inhibits growth of ER ⁺ breast cancer cell lines in vitro and in vivo .

HY-19822S3

Elacestrant-d6
Elacestrant-d₆ (RAD1901-d₆) is a deuterated labeled Elacestrant (HY-19822). Elacestrant is a selective estrogen receptor (estrogen receptor, ER) degrader (SERD) with oral activity, with IC₅₀ values of 48 and 870 nM for ERα and ERβ, respectively. Elacestrant can also effectively inhibit the growth of ER ⁺ breast cancer cell lines both in vitro and in vivo.

HY-19822S1

Elacestrant-d4-1
Elacestrant-d₄-1 is the deuterium labeled Elacestrant (HY-19822). Elacestrant is an orally available and selective estrogen receptor degrader (SERD) with IC₅₀s of 48 and 870 nM for ERα and ERβ, respectively .

HY-19822S

Elacestrant-d4
Elacestrant-d₄ (RAD1901-d₄) is a deuterated labeled Elacestrant (HY-19822). Elacestrant (RAD1901) is a selective estrogen receptor (estrogen receptor, ER) degrader (SERD) with oral activity, with IC₅₀ values of 48 and 870 nM for ERα and ERβ, respectively. Elacestrant can also effectively inhibit the growth of ER ⁺ breast cancer cell lines both in vitro and in vivo.

Cat. No.	Product Name		Classification

HY-139999A

LCL-PEG3-N3 hydrochloride		Azide
LCL-PEG3-N3 (hydrochloride) is a decoy oligonucleotide ligand for E3 ligase which can be used for developing chimeric molecules LCL-ER(dec), degrading the estrogen receptor . LCL-PEG3-N3 (hydrochloride) is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.

HY-139999

LCL-PEG3-N3		Azide
LCL-PEG3-N3 is a decoy oligonucleotide ligand for E3 ligase which can be used for developing chimeric molecules LCL-ER(dec), degrading the estrogen receptor . LCL-PEG3-N3 is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: